Concomitant Medications and Gastrointestinal Events in Thalassemia and MDS Patients Receiving Deferasirox for Transfusional Iron Overload: Data From the EPIC Study

被引：2
|
作者：
Cappellini, M. Domenica [1 ]
El-Beshlawy, Amal [2 ]
Porter, John B. [3 ]
Kattamis, Antonis [4 ]
Taylor, Kerry [5 ]
Rose, Christian [6 ]
Louw, Vernon J. [7 ]
El-Ali, Ali [8 ]
Martin, Nicolas [8 ]
Gattermann, Norbert [9 ]
机构：
[1] Univ Milan, Policlin Fdn IRCCS, Milan, Italy
[2] Cairo Univ, Cairo, Egypt
[3] UCL, London, England
[4] Univ Athens, Athens, Greece
[5] Mater Hosp, Brisbane, Qld, Australia
[6] Hop St Vincent de Paul, Lille, France
[7] Univ Free State, Bloemfontein, South Africa
[8] Novartis Pharma AG, Basel, Switzerland
[9] Univ Dusseldorf, D-40225 Dusseldorf, Germany
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.5182.5182
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5182
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Efficacy and Safety of Deferasirox (Exjade®) in Reducing Cardiac Iron in Patients with β-Thalassemia Major: Results from the Cardiac Substudy of the EPIC Trial
    Pennell, Dudley
    Porter, John B.
    Cappellini, Maria Domenica
    Li, Chi-Kong
    Aydinok, Yesim
    Lee, Chan Lee
    Kattamis, Antonis
    Smith, Gillian
    Habr, Dany
    Domokos, Gabor
    Hmissi, Abdel
    Taher, Ali
    BLOOD, 2008, 112 (11) : 1318 - 1318
  • [22] Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices
    Raptis, Anastasios
    Duh, Mei Sheng
    Wang, Si-Tien
    Dial, Ellison
    Fanourgiakis, Ilias
    Fortner, Barry
    Paley, Carole
    Mody-Patel, Nikita
    Corral, Mitra
    Scott, Jeffrey
    TRANSFUSION, 2010, 50 (01) : 190 - 199
  • [23] Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study
    Taher, Ali T.
    Porter, John B.
    Viprakasit, Vip
    Kattamis, Antonis
    Chuncharunee, Suporn
    Sutcharitchan, Pranee
    Siritanaratkul, Noppadol
    Galanello, Renzo
    Karakas, Zeynep
    Lawniczek, Tomasz
    Habr, Dany
    Ros, Jacqueline
    Zhu, Zewen
    Cappellini, M. Domenica
    ANNALS OF HEMATOLOGY, 2013, 92 (11) : 1485 - 1493
  • [24] Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study
    Ali T. Taher
    John B. Porter
    Vip Viprakasit
    Antonis Kattamis
    Suporn Chuncharunee
    Pranee Sutcharitchan
    Noppadol Siritanaratkul
    Renzo Galanello
    Zeynep Karakas
    Tomasz Lawniczek
    Dany Habr
    Jacqueline Ros
    Zewen Zhu
    M. Domenica Cappellini
    Annals of Hematology, 2013, 92 : 1485 - 1493
  • [25] Prospective Evaluation of the Effect of Deferasirox on Hematologic Response in Transfusion- Dependent Patients with Low-Risk MDS and Iron Overload: The Rythmex Study
    Rose, Christian
    Fitoussi, Olivier
    Gyan, Emmanuel
    Hacini, Maya
    Ame, Shanti
    Corront, Bernadette
    Beyne-Rauzy, Odile
    Adiko, Didier Innocent
    Loppinet, Elena-Anca
    Ali-Ammar, Nadia
    Wattel, Eric
    Dreyfus, Francois
    Cheze, Stephane
    BLOOD, 2016, 128 (22)
  • [26] IRON CHELATION THERAPY WITH DEFERASIROX (EXJADE®) IN REDUCING CARDIAC SIDEROSIS IN β-THALASSEMIA PATIENTS: 2-YEAR RESULTS FROM THE EPIC CARDIAC SUBSTUDY
    Pennell, Dudley J.
    Porter, John
    Cappellini, Domenica
    Chan, Lee Lee
    El-Beshlawy, Amal
    Aydinok, Yesim
    Ibrahim, Hishamshah
    Li, Chi-Kong
    Viprakasit, Vip
    Elalfy, Mohsen
    Kattamis, Antonis
    Smith, Gillian
    Habr, Dany
    Domokos, Gabor
    Roubert, Bernard
    Taher, Ali
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (10)
  • [27] Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study)
    Elli, Elena M.
    Iurlo, Alessandra
    Aroldi, Andrea
    Caramella, Marianna
    Malato, Simona
    Casartelli, Elena
    Maffioli, Margherita
    Gardellini, Angelo
    Carraro, Maria C.
    D'Adda, Mariella
    Polverelli, Nicola
    Rossi, Marianna
    Orofino, Nicola
    Carrer, Andrea
    Gamhacorti-Passerini, Carlo
    Antolini, Laura
    Passamonti, Francesco
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (05) : E123 - E126
  • [28] Summary of long-term renal safety data in transfused patients with secondary iron overload receiving deferasirox (Exjade®, ICL670).
    Bennett, W.
    Ponticelli, C.
    Piga, A.
    Kattamis, A.
    Glimm, E.
    Ford, J.
    BLOOD, 2006, 108 (11) : 30B - 30B
  • [29] CHANGES IN ALTERNATIVE IRON OVERLOAD PARAMETERS FOLLOWING 1 YEAR OF DEFERASIROX THERAPY IN PATIENTS WITH NON-TRANSFUSION-DEPENDENT THALASSEMIA: A LONGITUDINAL ANALYSIS FROM THE THALASSA STUDY
    Porter, J. B.
    Cappellini, M. D.
    Kattamis, A.
    Viprakasit, V.
    Musallam, K. M.
    Zhu, Z.
    Taher, A. T.
    HAEMATOLOGICA, 2014, 99 : 441 - 442
  • [30] Compliance and clinical benefit of deferasirox granule and dispersible tablet formulation in pediatric patients with transfusional iron overload: in a randomized, open-label, multicenter, phase II study
    Taher, Ali T.
    Wali, Yasser
    Cruz, Maria Cecilia
    Charoenkwan, Pimlak
    Aydinok, Yesim
    Werner, Olena
    Govindaraju, Sameera
    Romen, Fabian
    Viprakasit, Vip
    HAEMATOLOGICA, 2024, 109 (05) : 1413 - 1425
12345